Tag: book

BALLERUP, Denmark, June 04, 2026 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company specializing in advanced ceramic filtration solutions, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of approximately $20 million, prior to deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on June 8, 2026, subject to satisfaction of customary closing conditions.

The Miracle Hour teaches entrepreneurs to generate consistent revenue through one focused hour of daily relationship-based selling

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced that, in connection with its previously completed public offering of 15,000,000 shares of Class A common stock of the Company, including 7,698,410 shares being offered by affiliates of American Securities LLC (the “Selling Stockholders”) and 7,301,590 shares being offered by the Company, the underwriters have fully exercised their option to purchase an additional 2,250,000 shares of Class A common stock of the Company, including 1,154,760 shares from the Selling Stockholders and 1,095,240 from the Company at the public offering price of $36.00 per share, less underwriting discounts and commissions. The issuance and sale of the additional shares closed today.

Vantage Acquisition Anchors HHH’s Transformation into a Diversified Holding Company

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.